Cyclo Therapeutics Valuation
| CYTH Stock | USD 0.68 0.05 6.85% |
Cyclo Therapeutics is undervalued. Cyclo Therapeutics shows a prevailing Real Value of $1.74 per share. The current price of the firm is $0.68. Our model approximates the value of Cyclo Therapeutics from analyzing the firm fundamentals such as return on equity of -226.64, and Operating Margin of (45.78) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cyclo Therapeutics' valuation include:
Price Book 59.1038 | Enterprise Value 30.8 M | Enterprise Value Ebitda (0.47) | Price Sales 17.2035 | Enterprise Value Revenue 35.3257 |
Undervalued
Today
Please note that Cyclo Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Cyclo Therapeutics is based on 3 months time horizon. Increasing Cyclo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cyclo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cyclo Stock. However, Cyclo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.68 | Real 1.74 | Target 5.0 | Hype 0.67 |
The intrinsic value of Cyclo Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Cyclo Therapeutics' stock price.
Estimating the potential upside or downside of Cyclo Therapeutics helps investors to forecast how Cyclo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyclo Therapeutics more accurately as focusing exclusively on Cyclo Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Cyclo Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Cyclo Therapeutics Cash |
|
Cyclo Valuation Trend
Cyclo Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Cyclo Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Cyclo Therapeutics Total Value Analysis
Cyclo Therapeutics is currently anticipated to have valuation of 30.76 M with market capitalization of 19.48 M, debt of 1.03 M, and cash on hands of 4.29 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cyclo Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
30.76 M | 19.48 M | 1.03 M | 4.29 M |
Cyclo Therapeutics Investor Information
About 40.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.9. Cyclo Therapeutics last dividend was issued on the 9th of December 2020. The entity had 1:100 split on the 9th of December 2020. Based on the key indicators related to Cyclo Therapeutics' liquidity, profitability, solvency, and operating efficiency, Cyclo Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Cyclo Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cyclo Therapeutics has an asset utilization ratio of 8.13 percent. This signifies that the Company is making $0.0813 for each dollar of assets. An increasing asset utilization means that Cyclo Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Cyclo Therapeutics Ownership Allocation
Cyclo Therapeutics holds a total of 28.77 Million outstanding shares. Cyclo Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cyclo Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 1.23 M.About Cyclo Therapeutics Valuation
An absolute valuation paradigm, as applied to Cyclo Stock, attempts to find the value of Cyclo Therapeutics based on its fundamental and basic technical indicators. By analyzing Cyclo Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cyclo Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclo Therapeutics. We calculate exposure to Cyclo Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cyclo Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.4 M | -2.3 M | |
| Pretax Profit Margin | (18.63) | (17.70) | |
| Operating Profit Margin | (18.63) | (17.70) | |
| Net Loss | (18.63) | (17.70) | |
| Gross Profit Margin | 0.91 | 0.68 |
Cyclo Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.3 M | |
| Shares Float | 15.9 M |
Cyclo Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Cyclo Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cyclo we look at many different elements of the entity such as Cyclo's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cyclo Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cyclo Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cyclo Therapeutics' worth.Complementary Tools for Cyclo Stock analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |